• 1.

    Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

  • 2.

    U.S. Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Aug. 26, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin

    • Search Google Scholar
    • Export Citation
  • 3.

    Perkovic V, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Packer M, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:14131424. doi: 10.1056/NEJMoa2022190

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Zannad F, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced Trial. Circulation [published online ahead of print Oct. 23, 2020]. doi: 10.1161/CIRCULATIONAHA.120.051685

    • Search Google Scholar
    • Export Citation
  • 6.

    Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med [published online ahead of print Oct. 23, 2020]. doi: 10.1056/NEJMoa2025845; https://www.nejm.org/doi/full/10.1056/NEJMoa2025845

    • Search Google Scholar
    • Export Citation
  • 7.

    Agarwal R, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:15401550. doi: 10.1016/S0140-6736(19)32135-X

    • Crossref
    • Search Google Scholar
    • Export Citation

SGLT2 Inhibitors Continue to Show Kidney, Heart Benefits

Restricted access
Save